[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Gettinger, S., Horn, L., Jackman, D., et al. (2018) Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results from the CA209-003 Study. Journal of Clinical Oncology, 36, 1675-1684.
https://doi.org/10.1200/JCO.2017.77.0412
|
[3]
|
Tang, S., Qin, C., Hu, H., et al. (2022) Immune Checkpoint Inhib-itors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 11, Article No. 320. https://doi.org/10.3390/cells11030320
|
[4]
|
Lin, D., Yang, X., Jiang, L., et al. (2021) Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study. Journal of Thoracic Oncology, 16, S410.
https://doi.org/10.1016/j.jtho.2021.01.681
|
[5]
|
Rosenthal, R., Cadieux, E.L., Salgado, R., et al. (2019) Neoanti-gen-Directed Immune Escape in Lung Cancer Evolution. Nature, 567, 479-485. https://doi.org/10.1038/s41586-019-1032-7
|
[6]
|
Boussiotis, V.A. (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England Journal of Medicine, 375, 1767-1778. https://doi.org/10.1056/NEJMra1514296
|
[7]
|
Kim, K.H., Choi, K.U., Kim, A., et al. (2019) PD-L1 Expression on Stromal Tumor-Infiltrating Lymphocytes Is a Favorable Prognostic Factor in Ovarian Serous Carcinoma. Journal of Ovarian Research, 12, Article No. 56.
https://doi.org/10.1186/s13048-019-0526-0
|
[8]
|
Keir, M.E., Liang, S.C., Guleria, I., et al. (2006) Tissue Expres-sion of PD-L1 Mediates Peripheral T Cell Tolerance. The Journal of Experimental Medicine, 203, 883-895. https://doi.org/10.1084/jem.20051776
|
[9]
|
Xia, L., Liu, Y. and Wang, Y. (2019) PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. The Oncologist, 24, S31-S41.
https://doi.org/10.1634/theoncologist.2019-IO-S1-s05
|
[10]
|
Egen, J.G., Ouyang, W. and Wu, L.C. (2020) Human Anti-Tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 52, 36-54. https://doi.org/10.1016/j.immuni.2019.12.010
|
[11]
|
Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., et al. (2020) Clin-ical and Molecular Correlates of PD-L1 Expression in Patients with Lung Adenocarcinomas. Annals of Oncology, 31, 599-608. https://pubmed.ncbi.nlm.nih.gov/32178965/
https://doi.org/10.1016/j.annonc.2020.01.065
|
[12]
|
Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019) Pembroli-zumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[13]
|
Fonsatti, E., Nicolay, H.J.M., Sigalotti, L., et al. (2007) Functional Up-Regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-Aza-2’-Deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. Clinical Cancer Research, 13, 3333-3338. https://doi.org/10.1158/1078-0432.CCR-06-3091
|
[14]
|
Tseng, C.-W., Hung, C.-F., Alvarez, R.D., et al. (2008) Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vac-cination. Clinical Cancer Research, 14, 3185-3192.
https://doi.org/10.1158/1078-0432.CCR-08-0037
|
[15]
|
Pfirschke, C., Engblom, C., Rickelt, S., et al. (2016) Immu-nogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 44, 343-354. https://doi.org/10.1016/j.immuni.2015.11.024
|
[16]
|
陈思, 赵泽锐, 龙浩. 新辅助免疫治疗及联合化疗在NSCLC中的研究进展[J]. 中国肺癌杂志, 2021, 24(4): 284-292.
|
[17]
|
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092.
https://doi.org/10.1056/NEJMoa1801005
|
[18]
|
Garassino, M.C., Gadgeel, S., Esteban, E., et al. (2020) Pa-tient-Reported Outcomes Following Pembrolizumab or Placebo plus Pemetrexed and Platinum in Patients with Previous-ly Untreated, Metastatic, Non-Squamous Non-Small-Cell Lung Cancer (KEYNOTE-189): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 387-397. https://doi.org/10.1016/S1470-2045(19)30801-0
|
[19]
|
Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pembroli-zumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865
|
[20]
|
Paz-Ares, L., Vicente, D., Tafreshi, A., et al. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15, 1657-1669. https://doi.org/10.1016/j.jtho.2020.06.015
|
[21]
|
Mazieres, J., Kowalski, D., Luft, A., et al. (2020) Health-Related Quality of Life with Carboplatin-Paclitaxel or nab-Paclitaxel with or without Pembrolizumab in Patients with Metastatic Squamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 271-280. https://doi.org/10.1200/JCO.19.01348
|
[22]
|
关业兰, 胡红林, 金莹, 等. 帕博利珠单抗联合培美曲塞和卡铂对比培美曲塞和卡铂一线治疗晚期、非鳞状非小细胞肺癌: II期、随机、开放研究KEYNOTE-021G队列研究及长期随访数据解读[J]. 肿瘤学杂志, 2022, 28(9): 786-796.
|
[23]
|
Awad, M.A., Gadgeel, S.M., Borghaei, H., et al. (2021) Long-Term Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembroli-zumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology, 16, 162-168. https://pubmed.ncbi.nlm.nih.gov/33069888/
https://doi.org/10.1016/j.jtho.2020.09.015
|
[24]
|
Yang, Y., Sun, J., Wang, Z., et al. (2021) Updated Overall Survival Data and Predictive Biomarkers of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Ad-vanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Journal of Thoracic Oncology, 16, 2109-2120. https://doi.org/10.1016/j.jtho.2021.07.015
|
[25]
|
Nishio, M., Barlesi, F., West, H., et al. (2021) Atezoli-zumab plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results from the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 16, 653-664. https://doi.org/10.1016/j.jtho.2020.11.025
|
[26]
|
West, H., McCleod, M., Hussein, M., et al. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet, 20, 924-937.
https://doi.org/10.1016/S1470-2045(19)30167-6
|
[27]
|
张敏, 陈骏. 液体活检在非小细胞肺癌中的临床应用进展[J]. 中国肺癌杂志, 2021, 24(10): 723-728.
|